Skip to main content

Table 1 The baseline level of 2917 patients

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables Number Surgery (%) Non-surgery (%) χ2 P-value
Race      
White 2255 968 (42.9%) 1287 (57.1%) 0.567 0.753
Black 462 190 (41.1%) 272 (58.9%)   
Other 200 87 (43.5%) 113 (56.5%)   
Ethnic origin      
Spanish-Hispanic-Latino 289 136 (47.1%) 153 (52.9%) 2.513 0.113
Non-Spanish-Hispanic-Latino 2628 1109 (42.2%) 1519 (57.3%)   
Age      
 ≤ 35 134 67 (50%) 67 (50%) 21.613  < 0.001
35 < Age < 60 1345 631 (46%) 714 (54%)   
 ≥ 60 1438 547 (38%) 891 (62)   
Marital status      
Married 1416 662 (46.8%) 754 (53.2%) 18.638  < 0.001
Unmarried 1501 583 (38.8%) 918 (61.2%)   
Grade      
1 287 99 (34.5%) 188 (65.5%) 37.276  < 0.001
2 1440 560 (38.9%) 880 (68.1%)   
3–4 1190 586 (49.2%) 604 (50.8%)   
Laterality      
Left 1525 656 (43%) 869 (57%) 0.147 0.701
Right 1392 589 (42.3%) 803 (57.7%)   
Histology      
IDC 2351 1023 (43.5%) 1328 (56.5%) 3.433 0.064
Non-IDC 566 222 (39.2%) 344 (60.8%)   
T stage      
T1 383 153 (39.9%) 230 (60.1%) 45.68  < 0.001
T2 1158 569 (49.1%) 589 (50.9%)   
T3 553 242 (43.8%) 311 (56.2%)   
T4 823 281 (34.1%) 542 (65.9%)   
N stage      
N0 704 208 (29.5%) 496 (70.5%) 258.366  < 0.001
N1 1326 463 (34.9%) 863 (65.1%)   
N2 406 261 (64.3%) 145 (35.7)   
N3 481 313 (65.1%) 168 (34.9%)   
Radiation      
Yes 1302 704 (54.1%) 598 (45.9%) 124.703  < 0.001
No 1615 541 (33.5%) 1074 (66.5%)   
Chemotherapy      
Yes 1564 803 (51.3%) 761 (48.7%) 103.411  < 0.001
No 1353 442 (32.7%) 911 (67.3%)   
Subtype      
ER + /HER2− 2114 869 (41.1%) 1245 (58.9%) 11.671 0.009
ER + /HER2 +  433 189 (43.6%) 244 (56.4%)   
HER2 +  122 61 (50%) 61 (50%)   
TNBC 248 126 (50.8%) 122 (49.2%)   
ER      
Positive 2532 1050 (41.5%) 1482 (58.5%) 11.512 0.001
Negative 385 195 (50.6%) 190 (49.4%)   
PR      
Positive 2121 886 (41.8%) 1235 (58.2%) 2.62 0.106
Negative 796 359 (45.1%) 437 (54.9%)   
HER2      
Positive 555 250 (45%) 305 (55%) 1.566 0.211
Negative 2362 995 (42.1%) 1367 (57.9%)   
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, TNBC triple-negative breast cancer